Jean-Paul Kress
Chief Executive Officer at MORPHOSYS AG
Net worth: - $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Laurence J. Blumberg | M | 62 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 11 years |
| Seth Harrison | M | 63 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Marc Cluzel | M | 69 | 12 years | |
| Krisja Vermeylen | F | 62 | 7 years | |
| Günter Wellnhofer | M | - | 30 years | |
| Julia Neugebauer | M | - | 18 years | |
| Benoît Gueugnon | M | - | 6 years | |
| Andrew Cheng | M | 57 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 2 years |
| Daniel Palmacci | M | - | 4 years | |
| Richard S. Blumberg | M | - |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 11 years |
| Joseph Bratica | M | 60 | 7 years | |
| Luisa Ciccarelli | F | - | 3 years | |
| Thomas Biegi | M | - | 4 years | |
| Tim Demuth | M | 50 | 2 years | |
| Robert Mayer | M | - | 3 years | |
| Lucinda Crabtree | M | 45 | 1 years | |
| Ann Merchant | F | 59 | 6 years | |
| Jake Elkins | M | - | 7 years | |
| Sharon Curran | F | 56 | 5 years | |
| Anabella Villalobos | M | 65 | 7 years | |
| Ralf Ostendorp | M | - | 25 years | |
| Klaus de Wall | M | - | 19 years | |
| Barbara Krebs-Pohl | M | - | 26 years | |
| Ginger Gregory | M | 56 | 7 years | |
| Charlotte Lohmann | F | 54 | 12 years | |
| George Golumbeski | M | 67 | 6 years | |
| Michael Brosnan | M | 69 | 6 years | |
| Eamonn Nolan | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David de Graaf | M | - |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| William Goolsbee | M | 70 | 9 years | |
| Michael Halpin | M | 62 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 years |
| Ben Price | M | 68 | 9 years | |
| Malte Peters | M | 61 | 5 years | |
| Chirfi Guindo | M | 58 | 5 years | |
| Jeffrey Capello | M | 69 | 3 years | |
| Christophe Jurczak | M | - |
École Normale Supérieure
| 3 years |
| Melanie Rolli | M | 51 |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 3 years |
| Allene Diaz | F | 59 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 3 years |
| Markus Enzelberger | M | 55 | 18 years | |
| Roland Wandeler | M | 51 | 1 years | |
| Luc Dochez | M | 49 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 8 years |
| Anne Bouverot | M | 58 |
École Normale Supérieure
| 3 years |
| Didier Hoch | M | 68 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | - |
| Paul Clancy | M | 62 | 16 years | |
| Frank Morich | M | 69 | 5 years | |
| Simon Moroney | M | 65 | 27 years | |
| Sven Arne Andréasson | M | 72 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 14 years |
| Wendy Johnson | F | 72 | 7 years | |
| Yann Mazabraud | M | 51 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 1 years |
| Nithya Desikan | F | - | 1 years | |
| Franois Bastin | M | 52 |
École Normale Supérieure
| 4 years |
| Alpna Seth | M | 60 | 3 years | |
| Mark Hernon | M | - | 4 years | |
| Michael Mano | M | 47 | 2 years | |
| Arun Padmanabhan | M | - | 3 years | |
| David W Miller | M | - | 7 years | |
| Adriana Bokel Herde | F | - | 6 years | |
| Adam Hansard | M | 48 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 1 years |
| Robin A. Walker | M | 55 | 8 years | |
| Yue Hong Qian | M | 60 |
École Normale Supérieure
| 3 years |
| Katharina Kreymborg | M | - | 1 years | |
| Charles Monahan | M | - |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 4 years |
| Janice Olson | F | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
| Charbel Haber | M | - | 3 years | |
| Maria Castresana | F | - | 3 years | |
| Thomas-Christian Mix | M | 57 | 1 years | |
| Sanjay Jariwala | M | - | 2 years | |
| Karoline Shair | M | - | 2 years | |
| Vanya Sagar | F | 49 | 3 years | |
| Mishima Gerhart | F | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 2 years |
| Kenneth DiPietro | M | 65 | 5 years | |
| Joan Wood | F | - | 2 years | |
| Catherine Steele | F | - | 1 years | |
| Jens Holstein | M | 60 | 9 years | |
| Burt Adelman | M | 71 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 2 years |
| Stewart Craig | M | 63 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 2 years |
| Brian Schwab | M | 59 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 3 years |
| Christophe Bureau | M | 57 |
École Normale Supérieure
| 1 years |
| Jean-Sébastien Cleiftie | M | 50 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 5 years |
| Sam Hall | M | 42 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 4 years |
| Timothy Kelly | M | 55 | - | |
| Camille Lee | F | - | 1 years | |
| Joan Nickerson | F | 56 | 5 years | |
| Mario David Saltarelli | M | 63 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| John Koconis | M | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
| Aaron Kantoff | M | 29 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 4 years |
| Amy Chevalier Efantis | F | - | - | |
| Delphine Grison | M | 55 |
École Normale Supérieure
| 4 years |
| Remi Daudin | M | - |
École Normale Supérieure
| 4 years |
| Michael Panzara | M | 57 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 7 years |
| Jacques Le Pape | M | 56 |
École Normale Supérieure
| 4 years |
| Steven Avruch | M | 63 | 4 years | |
| David Ford | M | 56 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 1 years |
| Sung Lee | M | 53 | 2 years | |
| Gavin Malenfant | M | 61 | 1 years | |
| Anca Alexandru | M | - | - | |
| Alexander Scheer | M | 61 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 4 years |
| Richard Peters | M | 61 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 9 years |
| Catherine Stehman-Breen | M | 61 | - | |
| Noomane Fehri | M | - |
École Normale Supérieure
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 50 | 50.00% |
| Germany | 31 | 31.00% |
| France | 20 | 20.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jean-Paul Kress
- Personal Network
